Regenerative Therapies for Osteoarthritis Market Report 2026

The regenerative therapies for osteoarthritis market size has grown rapidly in recent years. It will grow from $3.04 billion in 2025 to $3.46 billion in 2026 at a compound annual growth rate (CAGR) of 13.9%. The growth in the historic period can be attributed to rising osteoarthritis prevalence, aging population growth, limitations of pain relief drugs, increase in sports injuries, demand for non surgical treatments.

The regenerative therapies for osteoarthritis market size is expected to see rapid growth in the next few years. It will grow to $5.88 billion in 2030 at a compound annual growth rate (CAGR) of 14.2%. The growth in the forecast period can be attributed to growth in biologic therapy adoption, expansion of regenerative clinics, increasing clinical evidence support, rising demand for cartilage restoration, higher investment in cell therapy research. Major trends in the forecast period include stem cell based joint repair therapies, platelet rich plasma treatment protocols, scaffold based cartilage regeneration, minimally invasive regenerative injections, personalized biologic therapy plans.

The increasing prevalence of musculoskeletal disorders is anticipated to drive the growth of the regenerative therapies for the osteoarthritis market in the coming years. Musculoskeletal disorders refer to conditions affecting bones, joints, muscles, and connective tissues that cause pain and limit mobility and dexterity. The growing prevalence of musculoskeletal disorders is largely driven by population aging, as older age groups experience higher rates of joint degeneration and inflammatory conditions affecting musculoskeletal structures. The rising incidence of musculoskeletal disorders boosts demand for regenerative therapies, as these therapies provide advanced treatment options for joint restoration and tissue repair in osteoarthritis patients. For example, in January 2024, according to the Office for Health Improvement & Disparities, a UK-based government agency, in 2023, 18.4% of individuals aged 16 and above reported having a long-term musculoskeletal (MSK) condition, up from 17.6% in 2022. Therefore, the increasing prevalence of musculoskeletal disorders is driving the growth of the regenerative therapies for the osteoarthritis market.

Companies operating in the regenerative therapies for the osteoarthritis market are focusing on developing advanced solutions, such as allogeneic mesenchymal stem cell (MSC) osteoarthritis therapies, to meet the rising demand for disease-modifying treatments. Allogeneic mesenchymal stem cell (MSC) osteoarthritis therapies use donor-sourced stem cells to modulate inflammation and support cartilage regeneration in affected joints, providing a ready-to-use, scalable option compared with patient-derived cells, allowing standardized dosing and wider adoption. For example, in December 2025, Cipla Limited, an India-based pharmaceutical company, partnered with Stempeutics Research, an India-based research and product development company, to launch Ciplostem, an innovative allogeneic MSC therapy for knee osteoarthritis. It is administered as a single-dose intra-articular injection containing 25 million cultured adult human bone marrow-derived MSCs co-formulated with hyaluronic acid, designed to work at the cellular level to reduce inflammation, slow disease progression, enhance joint function, and help preserve cartilage quality in Grade II and III knee OA patients. This therapy’s key features include off-the-shelf availability (no need for individualized preparation), cellular-level action versus symptomatic relief, and potential for prolonged improvement in joint health compared with standard regimens.

In January 2024, Smith+Nephew, a UK-based medical technology company, acquired CartiHeal for an undisclosed amount. Through this acquisition, Smith+Nephew seeks to strengthen its sports medicine business by expanding its regenerative knee repair portfolio with advanced cartilage regeneration technologies for osteochondral lesions and osteoarthritis treatment. CartiHeal is an Israel-based healthcare technology company specializing in Agili-C, a sports medicine technology for knee cartilage regeneration.

Major companies operating in the regenerative therapies for osteoarthritis market are Stryker Corporation, Smith & Nephew plc, MiMedx Group Inc, Anika Therapeutics Inc, Regentis Biomaterials Ltd, Zomedica Corp, Biosplice Therapeutics Inc, Tissue Regenix Group plc, Co.don AG, MEDIPOST Co Ltd, Ampio Pharmaceuticals Inc, Kolon TissueGene Inc, Mesoblast Limited, Orgenesis Inc, Hyalex Orthopaedics Limited, Orthocell Limited, Jellagen Limited, Hyalogic LLC, Bionaut Labs Inc, and Regeneus Limited.

Tariffs are affecting the regenerative therapies for osteoarthritis market by increasing the cost of imported cell processing equipment, biologic reagents, and laboratory consumables. Higher import duties are raising therapy preparation and administration costs across stem cell and PRP therapy segments. Specialty clinics and ambulatory centers that rely on imported kits and devices are most impacted. Regions dependent on global biotech supply chains, especially in asia pacific and parts of europe, are seeing cost variability. Providers are shifting toward locally produced kits and regional lab partnerships. Tariffs are also encouraging domestic production of regenerative therapy tools and consumables. This supports local biotech suppliers and improves supply continuity.

The regenerative therapies for osteoarthritis market research report is one of a series of new reports that provides regenerative therapies for osteoarthritis market statistics, including regenerative therapies for osteoarthritis industry global market size, regional shares, competitors with a regenerative therapies for osteoarthritis market share, detailed regenerative therapies for osteoarthritis market segments, market trends and opportunities, and any further data you may need to thrive in the regenerative therapies for osteoarthritis industry. This regenerative therapies for osteoarthritis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Regenerative therapies for osteoarthritis are advanced medical treatments focused on repairing, restoring, or replacing damaged cartilage and joint tissues rather than only managing symptoms. These therapies utilize biological methods such as stem cells, platelet-rich plasma (PRP), growth factors, and tissue-engineered solutions to stimulate natural healing, reduce inflammation, improve joint function, and potentially slow or reverse disease progression.

The core therapy types of regenerative therapies for osteoarthritis comprise stem cell therapy, platelet-rich plasma therapy, tissue engineering, gene therapy, and other therapy types. Stem cell therapy involves using stem cells to repair or regenerate damaged cartilage and tissues in joints affected by osteoarthritis. These therapies are distributed through channels such as direct manufacturer supply, hospital and clinic procurement, and specialty medical distributors. They are applied to conditions including knee osteoarthritis, hip osteoarthritis, hand osteoarthritis, and other related applications, and are used by hospitals, ambulatory surgical centers, specialty clinics, and other end-users.

The regenerative therapies for osteoarthritis market includes revenues earned by entities through clinical consultation, patient assessment, therapy administration, regenerative cell preparation, tissue engineering support, post-treatment monitoring, rehabilitation support, laboratory testing, personalized treatment planning, and regulatory compliance support. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.